Prohost BiotechResearch Platform

Home Articles Prohost LettersAveXis Drug’s Data for Spinal Muscular Atrophy Highlights Gene Therapy

Prohost Letters

Premium

AveXis Drug’s Data for Spinal Muscular Atrophy Highlights Gene Therapy

The Week in Review #21 Part 2 THE MARKET (2) - Our remarks in the past Week in Review included our confidence that the attempts by negative investors to drive the market crazy will not deprive the ma...

P

Prohost Biotech

April 30, 2018

1 min read

7

0

Unlock Premium Content

This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.

Unlimited articles

Expert analysis

Research reports

Tags

AveXis Inc (AVXS)

Cellectis (CLLS)

CRISPR Therapeutics (CRSP)

Editas Medicine Inc (EDIT)

ImmunoGen (IMGN)

Intellia Therapeutics (NTLA)

Prohost Portfolio

Sangamo Therapeutics Inc (SGMO)

Spark Therapeutics

Comments (0)

Please sign in to join the discussion

Related Articles

Prohost Letters

Prohost Letter #461 ~ Preventing HIV Infection and Treating Primary Biliary Cholangitis

Prohost Letter #461 Preventing HIV Infection and Treating Primary Biliary Cholangitis Gilead Sciences Gilead Sciences’ ( GILD ) stock price has been paralyzed for more than three consecutive years. T...

Prohost Biotech

Aug 21, 2024

Prohost Letters

Prohost Letter #460 ~ Treating IgA Nephropathy

Prohost Letter #460 Treating IgA Nephropathy Immunoglobulin A ( IgA ), the antibody of the immune system known to fight infections, can itself cause two important diseases. It can attack the body caus...

Prohost Biotech

Jun 1, 2024

Prohost Letters

Prohost Letter #459 ~ NAFLD & NASH

Prohost Letter #459 ~ NAFLD & NASH NAFLD is Non-Alcoholic Fatty Liver Disease, and NASH is Non-Alcoholic Steatohepatitis. We will start with NAFLD. NAFLD The Non-Alcoholic Fatty Liver Disease is cau...

Prohost Biotech

Mar 3, 2024